RedHill Biopharma raises at-the-market offering cap

This report is incorporated by reference into RedHill Biopharma's Form S-8 and Form F-3 registration statements.

Rhea-AI Filing Summary

RedHill Biopharma Ltd. filed a prospectus supplement increasing the maximum aggregate offering amount of American Depositary Shares it may issue and sell from time to time under its at-the-market offering agreement with H.C. Wainwright & Co., LLC. Each American Depositary Share represents 10,000 ordinary shares. The report is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.

Key Figures

ADS-to-ordinary-share ratio: 10,000 ordinary shares per American Depositary Share

1 metrics

ADS-to-ordinary-share ratio 10,000 ordinary shares per American Depositary Share Each American Depositary Share represents this number of ordinary shares.

Key Terms

At The Market Offering Agreement, American Depositary Shares, prospectus supplement

3 terms

At The Market Offering Agreement financial

"under the At The Market Offering Agreement"

An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.

American Depositary Shares financial

"American Depositary Shares, each representing ten thousand (10,000) of its ordinary shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

prospectus supplement financial

"filed a prospectus supplement to increase the maximum aggregate offering amount"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ordinary shares does each RDHL ADS represent?

Each American Depositary Share represents 10,000 ordinary shares.

When did RDHL enter its at-the-market offering agreement with H.C. Wainwright?

RedHill Biopharma entered the agreement with H.C. Wainwright & Co., LLC on February 3, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 04:10 PM EDT Accepted by SEC EDGAR 10/13/2026 - 04:10 PM EDT Learn about SEC filing dates

 UNITED STATES   

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October 2026
Commission File No.:001-35773

REDHILL BIOPHARMA LTD. 

(Translation of registrant’s name into English)

21 Ha’arba’a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 
On October 13, 2026, RedHill Biopharma Ltd. (the “Company”) filed a prospectus supplement to increase the maximum aggregate offering amount of the American Depositary Shares, each representing ten thousand (10,000) of its ordinary shares, no par value, that may be issued and sold from time to time under the At The Market Offering Agreement that the Company entered into with H.C. Wainwright & Co., LLC on February 3, 2025.

Attached hereto and incorporated by reference in this Report on Form 6-K are the following exhibits:

Exhibit 5.1: Goldfarb Gross Seligman & Co..

Exhibit 5.2: Opinion of Haynes and Boone, LLP.

Exhibit 23.1: Consent of Goldfarb Gross Seligman & Co. (included in Exhibit 5.1).

Exhibit 23.2: Consent of Haynes and Boone, LLP (included in Exhibit 5.2).

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, on August 9, 2024 (File No. 333-281417) and on July 2, 2026 (333-297223).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the “Registrant”)
Date: October 13, 2026	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

2 documents

Other Documents

• EX-5.1 EXHIBIT 5.1 9.8 KB
• EX-5.2 EXHIBIT 5.2 9.8 KB